We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
+4.85%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$721M
AUM Growth
+$3.8M
Cap. Flow
-$22.4M
Cap. Flow %
-3.1%
Top 10 Hldgs %
29.13%
Holding
154
New
13
Increased
38
Reduced
45
Closed
15

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$6.22M
2
COR icon
Cencora
COR
+$5.63M
3
ILMN icon
Illumina
ILMN
+$5.46M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.98M
5
PRGO icon
Perrigo
PRGO
+$4.77M

Top Sells

Rank Stock Value
1
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$18.9M
2
BAX icon
Baxter International
BAX
+$9.56M
3
CNC icon
Centene
CNC
+$8.47M
4
LCI
Lannett Company, Inc.
LCI
+$6.61M
5
MOH icon
Molina Healthcare
MOH
+$6.39M

Sector Composition

Rank Sector Weight
1 Healthcare 90.06%
2 Financials 0.8%
3 Industrials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IPXL
101
DELISTED
Impax Laboratories, Inc.
IPXL
$1.5M 0.21%
32,600
– –
QGENF
102
DELISTED
QIAGEN NV
QGENF
$1.49M 0.21%
60,000
– –
ABUS icon
103
Arbutus Biopharma
ABUS
$907M
$1.48M 0.21%
+125,000
New +$1.9M
MYGN icon
104
Myriad Genetics
MYGN
$315M
$1.29M 0.18%
38,000
+14,000
+58% +$476K
IMMU
105
DELISTED
Immunomedics Inc
IMMU
$1.22M 0.17%
300,000
-100,000
-25% -$409K
LH icon
106
Labcorp
LH
$25.9B
$1.21M 0.17%
11,640
– –
CNC icon
107
Centene
CNC
$32.7B
$1.21M 0.17%
30,000
-235,840
-89% -$8.47M
XOMA
108
DELISTED
Xoma
XOMA
$1.15M 0.16%
14,750
– –
JNP
109
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$1.01M 0.14%
110,000
– –
KANG
110
DELISTED
iKang Healthcare Group, Inc.
KANG
$967K 0.13%
+50,000
New +$919K
ATHN
111
DELISTED
Athenahealth, Inc.
ATHN
$917K 0.13%
8,000
-10,000
-56% -$1.2M
NVDQ
112
DELISTED
Novadaq Technologies Inc.
NVDQ
$915K 0.13%
75,598
+5,598
+8% +$66.9K
AFFX
113
DELISTED
Affymetrix Inc
AFFX
$874K 0.12%
80,000
-20,000
-20% -$242K
RMD icon
114
ResMed
RMD
$31.8B
$846K 0.12%
15,000
-5,000
-25% -$316K
ECYT
115
DELISTED
Endocyte, Inc. Common Stock
ECYT
$820K 0.11%
158,000
-32,215
-17% -$193K
DYAX
116
DELISTED
DYAX CORPORATION
DYAX
$795K 0.11%
30,000
– –
ELGX
117
DELISTED
Endologix Inc
ELGX
$767K 0.11%
5,000
– –
PRTA icon
118
Prothena Corp
PRTA
$444M
$685K 0.1%
+13,000
New +$513K
ABMD
119
DELISTED
Abiomed Inc
ABMD
$657K 0.09%
10,000
-10,000
-50% -$664K
INVA icon
120
Innoviva
INVA
$1.5B
$632K 0.09%
35,000
– –
TSRO
121
DELISTED
TESARO, Inc.
TSRO
$606K 0.08%
10,300
– –
TTPH
122
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$569K 0.08%
600
– –
SGMO
123
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$555K 0.08%
50,000
– –
MDSO
124
DELISTED
Medidata Solutions, Inc.
MDSO
$543K 0.08%
10,000
-10,000
-50% -$537K
TNDM icon
125
Tandem Diabetes Care
TNDM
$1.56B
$542K 0.08%
5,000
– –
3 4
5
6 7

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.5% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.57% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q2 2015 Portfolio in Review

As of Q2 2015, Bellevue Asset Management (Switzerland) held 154 positions worth $721M, up 0.53% from $717M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Asset Management (Switzerland) withdrew a net $22.4M in Q2 2015, closing 15 positions and reducing 45 holdings. Its most notable exit was CATAMARAN CORP COM STK (CDA), an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Bellevue Asset Management (Switzerland) opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $5.21M.

  • Bellevue Asset Management (Switzerland)'s largest Q2 2015 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 150,000 shares worth $5.21M.
  • Bellevue Asset Management (Switzerland) added most to Endo International plc in Q2 2015, an estimated $6.22M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q2 2015 reduction was Centene, cutting an estimated $8.47M.
  • Bellevue Asset Management (Switzerland) fully exited CATAMARAN CORP COM STK (CDA) in Q2 2015, selling an estimated $18.9M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 29% of its $721M portfolio in Q2 2015.
  • Bellevue Asset Management (Switzerland) opened 13 new positions and closed 15 in Q2 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value rose 0.53% quarter-over-quarter to $721M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q2 2015, filed 12 Aug 2015.